What is Eupraxia?
Eupraxia Pharmaceuticals Inc. operates as a clinical-stage biotechnology enterprise dedicated to the discovery, development, and commercialization of advanced medical technologies. The company's core competency lies in its specialized drug delivery systems, designed to provide sustained release of therapeutic agents. Its lead candidate, EP-104IAR, is currently undergoing Phase III clinical trials for the treatment of knee osteoarthritis, representing a significant milestone in the company's clinical trajectory. Furthermore, the firm maintains a diverse portfolio, including EP-104GI for eosinophilic esophagitis and various preclinical programs targeting inflammatory joint conditions and oncology. By focusing on localized delivery mechanisms, Eupraxia aims to improve patient outcomes while minimizing systemic side effects, thereby carving out a distinct competitive advantage in the pharmaceutical landscape.
How much funding has Eupraxia raised?
Eupraxia has raised a total of $70M across 2 funding rounds:
Debt
$8M
Share Placement
$62M
Debt (2021): $8M with participation from Silicon Valley Bank
Share Placement (2024): $62M, investors not publicly disclosed
Key Investors in Eupraxia
Silicon Valley Bank
SVB Financial Group offers commercial and private banking, asset management, private wealth management, brokerage and investment services, funds management, and business valuation services. The company was founded in 1983 and is headquartered in Santa Clara, California.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Eupraxia?
Looking ahead, the strategic deployment of the $62M will be instrumental in advancing Eupraxia's clinical pipeline through critical regulatory milestones. The company is expected to prioritize the completion of its Phase III trials for EP-104IAR, a move that could fundamentally alter its market valuation and commercial potential. Additionally, the firm will likely allocate resources toward the expansion of its preclinical oncology programs, further diversifying its therapeutic reach. As Eupraxia moves deeper into the commercialization phase, the focus will shift toward scaling manufacturing capabilities and establishing strategic partnerships to facilitate the eventual market entry of its lead candidates. This growth trajectory suggests a long-term commitment to innovation in the biotechnology space, with a clear roadmap for addressing complex, chronic medical conditions.
See full Eupraxia company page
